Age-related differences in presentation and outcomes of anti-VEGF treatment of retinal vein occlusion

Abstract

ObjectiveTo assess age-related differences at baseline and treatment outcomes in patients with retinal vein occlusion (RVO) and macular edema treated with anti-vascular endothelial growth factor (VEGF) therapy DesignSingle-centre retrospective chart review. Participants295 treatment-naïve RVO patients. Methods295 RVO patients included were separated into age quartiles: group A (22–61 years), group B (62–70 years), group C (71–79 years), and group D (80–95 years). Outcomes including central subfield thickness (CST), cubic volume, cubic average thickness, and visual acuity (VA) were collected at baseline and at 6 and 12 months after treatment. The primary outcome of the study was the CST at 12 months after anti-VEGF therapy. ResultsMean baseline CST for groups A, B, C, and D was 406.3 ± 161.2 μm, 463.4 ± 165.5 μm, 470.6 ± 187 μm, and 427.3 ± 187.2 μm, respectively. No significant differences in CST were observed between groups at baseline, 6 months, or 12 months (p ≥ 0.08). Mean baseline VA for groups A, B, C, and D was 55.8 ± 19.5, 54.4 ± 19.8, 54.7 ± 19, and 51.4 ± 20.4 Early Treatment Diabetic Retinopathy letters, respectively. VA did not differ significantly between age groups at baseline, 6 months, or 12 months (p ≥ 0.06). ConclusionsThe presentation of RVO and the visual outcomes of anti-VEGF therapy do not vary based on age.